This site is intended for healthcare professionals

Lumakras receives approval in Japan for patients with KRAS G12C mutated advanced NSCLC.

Read time: 1 mins
Published:21st Jan 2022
Amgen announced that Lumakras (sotorasib) has been approved in Japan for the treatment of KRAS G12C-mutated positive, unresectable, advanced and/or recurrent non-small cell lung cancer (NSCLC) that has progressed after systemic anticancer therapy.

The approval by the Japan Ministry of Health, Labour and Welfare (MHLW) is based on positive results from the Phase II CodeBreaK 100 clinical trial in NSCLC, the largest trial conducted to date for patients with the KRAS G12C mutation. Based on the approved label in Japan, Lumakras 960 mg, orally administered once-daily, demonstrated an objective response rate (ORR) of 37% (95% CI: 28.8-46.6) in 123 evaluable patients (including 10 Japanese patients with a data cutoff date: Sept. 1, 2020). Adverse reactions were observed in 128 (67%) of 190 patients (including 13 Japanese patients). The most common adverse reactions (incidence greater than 5%) were diarrhea (28%), nausea, increased alanine aminotransferase (ALT) and increased aspartate aminotransferase (AST) (16% each), fatigue (11%), increased blood alkaline phosphatase (8%), vomiting (7%) and abdominal pain (5%).

Results from the Phase II CodeBreaK clinical trial in NSCLC were published in The New England Journal of Medicine. (previously cited)

Condition: NSCLC/KRAS G12C
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.